REG - Ergomed plc - FDA removal of hold on Ph3 trial with Multikine <Origin Href="QuoteRef">ERGO.L</Origin>
RNS Number : 9319NErgomed plc14 August 2017PRESS RELEASE
Ergomed notes announcement by co-development partner, CEL-SCI, of FDA removal of clinical hold on Phase 3 clinical trial with Multikine in head and neck cancer
London, UK - 14 August 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a specialised pharmaceutical services and drug development company, notes that its co-development partner CEL-SCI has announced that the US Food and Drug Administration (FDA) has removed the clinical hold on the current Phase 3 study with Multikinein head and neck cancer.
All clinical trial activities can now be resumed. Nine-hundred and twenty-eight (928) newly diagnosed head and neck cancer patients have been enrolled in this Phase 3 study and all the patients who have completed treatment continue to be followed for protocol-specific outcomes in accordance with the Study Protocol.
Dr. Dan Weng, Chief Executive Officer of Ergomed, said: "We're very pleased to hear that the Phase 3 study of Multikine in head and neck cancer has been approved for continuation by the FDA. Multikine addresses a significant unmet medical need and we look forward to continuing to work with CEL-SCI on what is the largest ever Phase III study in head and neck cancer."
The full announcement from CEL-SCI can be found on its website: www.cel-sci.com.
ENDS
Enquiries:
Ergomed plc
Tel: +44 (0) 1483 503205
Dan Weng (Chief Executive Officer)
Stephen Stamp (Chief Financial Officer)
Numis Securities Limited
Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black (Joint Broker)
N+1 Singer
Tel: +44 (0) 20 7496 3000
Alex Price (Joint Broker)
Consilium Strategic Communications - for UK enquiries
Tel: +44 (0) 20 3709 5700
Chris Gardner / Mary-Jane Elliott
Ivar Milligan / Philippa Gardner
ergomed@consilium-comms.com
MC Services - for Continental European enquiries
Tel: +49 211 5292 5222
Anne Hennecke
About Ergomed
Ergomed provides specialist services to the pharmaceutical industry and develops drugs both wholly-owned and through partnerships. Ergomed's fast-growing, profitable service offering spans all phases of clinical development and post-approval pharmacovigilance and medical information. Drawing on more than 20 years of expertise in drug development, Ergomed is also building a growing portfolio of drug development partnerships and programmes, including wholly-owned proprietary products for the treatment of surgical bleeding. For further information, visit: http://ergomedplc.com.
This information is provided by RNSThe company news service from the London Stock ExchangeENDMSCGGUMPRUPMGGC
Recent news on Ergomed
See all newsREG - Ergomed plc - Cancellation of admission to trading of shares
AnnouncementREG - AIM Ergomed plc - Cancellation - Ergomed plc
AnnouncementREG - Takeover Panel - Disclosure Table
AnnouncementREG-Millennium Partners, L.P. Form 8.3 - Ergomed plc
AnnouncementREG - BlackRock Group Ergomed plc - Form 8.3 - Ergomed plc
Announcement